JP2012505250A5 - - Google Patents

Download PDF

Info

Publication number
JP2012505250A5
JP2012505250A5 JP2011531226A JP2011531226A JP2012505250A5 JP 2012505250 A5 JP2012505250 A5 JP 2012505250A5 JP 2011531226 A JP2011531226 A JP 2011531226A JP 2011531226 A JP2011531226 A JP 2011531226A JP 2012505250 A5 JP2012505250 A5 JP 2012505250A5
Authority
JP
Japan
Prior art keywords
lipid
polypeptide
pharmaceutical composition
sirna
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011531226A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012505250A (ja
JP5777519B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/060251 external-priority patent/WO2010042877A1/en
Publication of JP2012505250A publication Critical patent/JP2012505250A/ja
Publication of JP2012505250A5 publication Critical patent/JP2012505250A5/ja
Application granted granted Critical
Publication of JP5777519B2 publication Critical patent/JP5777519B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011531226A 2008-10-09 2009-10-09 改良されたアミノ脂質および核酸の送達方法 Expired - Fee Related JP5777519B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US10421908P 2008-10-09 2008-10-09
US10421208P 2008-10-09 2008-10-09
US61/104,219 2008-10-09
US61/104,212 2008-10-09
US22066609P 2009-06-26 2009-06-26
US61/220,666 2009-06-26
PCT/US2009/060251 WO2010042877A1 (en) 2008-10-09 2009-10-09 Improved amino lipids and methods for the delivery of nucleic acids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014194789A Division JP6077509B2 (ja) 2008-10-09 2014-09-25 改良されたアミノ脂質および核酸の送達方法

Publications (3)

Publication Number Publication Date
JP2012505250A JP2012505250A (ja) 2012-03-01
JP2012505250A5 true JP2012505250A5 (OSRAM) 2012-11-22
JP5777519B2 JP5777519B2 (ja) 2015-09-09

Family

ID=42100987

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2011531226A Expired - Fee Related JP5777519B2 (ja) 2008-10-09 2009-10-09 改良されたアミノ脂質および核酸の送達方法
JP2014194789A Expired - Fee Related JP6077509B2 (ja) 2008-10-09 2014-09-25 改良されたアミノ脂質および核酸の送達方法
JP2016160375A Withdrawn JP2016196508A (ja) 2008-10-09 2016-08-18 改良されたアミノ脂質および核酸の送達方法
JP2018094076A Expired - Fee Related JP6505912B2 (ja) 2008-10-09 2018-05-15 改良されたアミノ脂質および核酸の送達方法
JP2019060423A Pending JP2019137688A (ja) 2008-10-09 2019-03-27 改良されたアミノ脂質および核酸の送達方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2014194789A Expired - Fee Related JP6077509B2 (ja) 2008-10-09 2014-09-25 改良されたアミノ脂質および核酸の送達方法
JP2016160375A Withdrawn JP2016196508A (ja) 2008-10-09 2016-08-18 改良されたアミノ脂質および核酸の送達方法
JP2018094076A Expired - Fee Related JP6505912B2 (ja) 2008-10-09 2018-05-15 改良されたアミノ脂質および核酸の送達方法
JP2019060423A Pending JP2019137688A (ja) 2008-10-09 2019-03-27 改良されたアミノ脂質および核酸の送達方法

Country Status (9)

Country Link
US (2) US9139554B2 (OSRAM)
EP (3) EP2350043B9 (OSRAM)
JP (5) JP5777519B2 (OSRAM)
CN (2) CN104119242B (OSRAM)
AU (1) AU2009303345B2 (OSRAM)
CA (2) CA2740000C (OSRAM)
ES (1) ES2475065T3 (OSRAM)
PL (1) PL2350043T3 (OSRAM)
WO (1) WO2010042877A1 (OSRAM)

Families Citing this family (562)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
AU2006322076C1 (en) 2005-12-08 2013-11-14 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US8324277B2 (en) 2007-08-01 2012-12-04 University of Pittsburgh—of the Commonwealth System of Higher Education Nitrated-fatty acids modulation of type II diabetes
CA2710713C (en) 2007-12-27 2017-09-19 Protiva Biotherapeutics, Inc. Silencing of polo-like kinase expression using interfering rna
US8058069B2 (en) 2008-04-15 2011-11-15 Protiva Biotherapeutics, Inc. Lipid formulations for nucleic acid delivery
CN102083787A (zh) 2008-05-01 2011-06-01 康普雷克萨公司 乙烯基取代的脂肪酸
WO2009155439A2 (en) 2008-06-19 2009-12-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
WO2010042877A1 (en) * 2008-10-09 2010-04-15 Tekmira Pharmaceuticals Corporation Improved amino lipids and methods for the delivery of nucleic acids
AU2015249072C1 (en) * 2008-10-20 2022-10-27 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of transthyretin
HRP20150796T1 (hr) 2008-10-20 2015-09-11 Alnylam Pharmaceuticals, Inc. Pripravci i postupci za inhibiciju ekspresije transtiretina
MX353900B (es) 2008-11-07 2018-02-01 Massachusetts Inst Technology Lipidoides de aminoalcohol y usos de los mismos.
WO2010054384A1 (en) 2008-11-10 2010-05-14 Alnylam Pharmaceuticals, Inc. Lipids and compositions for the delivery of therapeutics
CN105152939A (zh) * 2008-11-10 2015-12-16 阿尔尼拉姆医药品有限公司 用于递送治疗剂的脂质和组合物
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
EP3243504A1 (en) * 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Improved lipid formulation
CN102421900B (zh) * 2009-03-12 2015-07-22 阿尔尼拉姆医药品有限公司 用于抑制Eg5和VEGF基因表达的脂质配制的组合物以及方法
CA3045126A1 (en) * 2009-05-05 2010-11-11 Arbutus Biopharma Corporation Methods of delivering oligonucleotides to immune cells
KR20230098713A (ko) 2009-06-10 2023-07-04 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
EP2442792A4 (en) * 2009-06-15 2015-12-23 Alnylam Pharmaceuticals Inc TESTING GENE PCSK9 LIPID-FORMULATED DSRNA
WO2010147992A1 (en) 2009-06-15 2010-12-23 Alnylam Pharmaceuticals, Inc. Methods for increasing efficacy of lipid formulated sirna
EP2449106B1 (en) * 2009-07-01 2015-04-08 Protiva Biotherapeutics Inc. Compositions and methods for silencing apolipoprotein b
EP2449114B9 (en) 2009-07-01 2017-04-19 Protiva Biotherapeutics Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
WO2011011447A1 (en) 2009-07-20 2011-01-27 Protiva Biotherapeutics, Inc. Compositions and methods for silencing ebola virus gene expression
JP2013500966A (ja) 2009-07-31 2013-01-10 ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション 抗炎症剤としての脂肪酸
US9181295B2 (en) 2009-08-20 2015-11-10 Sirna Therapeutics, Inc. Cationic lipids with various head groups for oligonucleotide delivery
US9222086B2 (en) 2009-09-23 2015-12-29 Protiva Biotherapeutics, Inc. Compositions and methods for silencing genes expressed in cancer
US8686167B2 (en) 2009-10-02 2014-04-01 Complexa, Inc. Heteroatom containing substituted fatty acids
JP5723378B2 (ja) * 2009-11-03 2015-05-27 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． トランスサイレチン（ｔｔｒ）を阻害する脂質製剤化組成物及び方法
EP3403647A1 (en) 2009-12-01 2018-11-21 Translate Bio, Inc. Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
US8846631B2 (en) * 2010-01-14 2014-09-30 Regulus Therapeutics Inc. MicroRNA compositions and methods
EP2525781A1 (en) 2010-01-22 2012-11-28 Schering Corporation Novel cationic lipids for oligonucleotide delivery
EP3391877A1 (en) 2010-04-08 2018-10-24 The Trustees of Princeton University Preparation of lipid nanoparticles
EP2567952A4 (en) * 2010-04-28 2015-11-25 Kyowa Hakko Kirin Co Ltd CATIONIC LIPID
US9408914B2 (en) 2010-04-28 2016-08-09 Kyowa Hakko Kirin Co., Ltd. Cationic lipid
US8865675B2 (en) 2010-05-12 2014-10-21 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein B
US10077232B2 (en) 2010-05-12 2018-09-18 Arbutus Biopharma Corporation Cyclic cationic lipids and methods of use
US20130123338A1 (en) * 2010-05-12 2013-05-16 Protiva Biotherapeutics, Inc. Novel cationic lipids and methods of use thereof
EP2575895A2 (en) 2010-05-24 2013-04-10 Merck Sharp & Dohme Corp. Novel amino alcohol cationic lipids for oligonucleotide delivery
NZ605079A (en) 2010-06-03 2015-08-28 Alnylam Pharmaceuticals Inc Biodegradable lipids for the delivery of active agents
WO2012000104A1 (en) 2010-06-30 2012-01-05 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
EP2591114B1 (en) 2010-07-06 2016-06-08 GlaxoSmithKline Biologicals SA Immunisation of large mammals with low doses of rna
DK3243526T3 (da) 2010-07-06 2020-02-17 Glaxosmithkline Biologicals Sa Levering af rna til at udløse flere immunsignalveje
BR112013000244A2 (pt) 2010-07-06 2016-05-17 Novartis Ag lipossomas com lipídeos apresentando pka vantajoso para administração de rna
PL2590676T3 (pl) 2010-07-06 2017-02-28 Glaxosmithkline Biologicals Sa Wirionopodobne cząstki dostarczające dla autoreplikujących się cząsteczek rna
US20130323269A1 (en) * 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3587574B1 (en) 2010-08-17 2022-03-16 Sirna Therapeutics, Inc. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
EP2609106A4 (en) 2010-08-26 2014-03-19 Merck Sharp & Dohme RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2012027675A2 (en) 2010-08-26 2012-03-01 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
EP2611927B1 (en) 2010-08-31 2018-08-01 Sirna Therapeutics, Inc. Novel single chemical entities and methods for delivery of oligonucleotides
RS63315B1 (sr) 2010-08-31 2022-07-29 Glaxosmithkline Biologicals Sa Pegilovani lipozomi za isporuku rnk koja kodira imunogen
WO2012031205A2 (en) 2010-09-03 2012-03-08 The Brigham And Women's Hospital, Inc. Lipid-polymer hybrid particles
US8466122B2 (en) 2010-09-17 2013-06-18 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
MX349088B (es) 2010-09-20 2017-07-10 Merck Sharp & Dohme Lípidos catiónicos novedosos de bajo peso molecular para la entrega de oligonucleótidos.
JP2013545723A (ja) 2010-09-30 2013-12-26 メルク・シャープ・エンド・ドーム・コーポレイション オリゴヌクレオチドの送達のための低分子量カチオン性脂質
EP3431485B2 (en) 2010-10-01 2024-09-04 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
CA2814386C (en) 2010-10-11 2019-08-20 Novartis Ag Antigen delivery platforms
JP2013545727A (ja) 2010-10-21 2013-12-26 メルク・シャープ・アンド・ドーム・コーポレーション オリゴヌクレオチド送達用の新規低分子量カチオン性脂質
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
DK2635265T3 (en) 2010-11-05 2018-07-16 Sirna Therapeutics Inc New low molecular weight cyclic amine-containing cationic lipids for oligonucleotide delivery
US8853377B2 (en) 2010-11-30 2014-10-07 Shire Human Genetic Therapies, Inc. mRNA for use in treatment of human genetic diseases
US9238716B2 (en) 2011-03-28 2016-01-19 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
US20140206753A1 (en) 2011-06-08 2014-07-24 Shire Human Genetic Therapies, Inc. Lipid nanoparticle compositions and methods for mrna delivery
CA3198966A1 (en) 2011-06-08 2012-12-13 Translate Bio, Inc. Cleavable lipids
EP4115875A1 (en) 2011-07-06 2023-01-11 GlaxoSmithKline Biologicals S.A. Liposomes having useful n:p ratio for delivery of rna molecules
CA2840989A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
WO2013028501A1 (en) 2011-08-19 2013-02-28 The University Of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
US9126966B2 (en) * 2011-08-31 2015-09-08 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9271952B2 (en) 2011-10-11 2016-03-01 Complexa, Inc. Compositions and methods for treating nephropathy
PE20181541A1 (es) 2011-10-27 2018-09-26 Massachusetts Inst Technology Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco
MY167390A (en) * 2011-11-18 2018-08-16 Alnylam Pharmaceuticals Inc Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
CA2856742A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
WO2013086373A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
JP6305343B2 (ja) * 2011-12-07 2018-04-04 アルニラム・ファーマシューティカルズ・インコーポレーテッド 活性薬剤の送達のための分岐アルキルおよびシクロアルキルを末端とする生分解性脂質
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
DK2806896T3 (en) 2012-01-27 2018-03-05 Hoffmann La Roche Chitosan covalently bound to small molecule integrin antagonist for targeted delivery
US20130197059A1 (en) 2012-01-27 2013-08-01 Hoffmann-La Roche Inc. Integrin antagonist conjugates for targeted delivery to cells expressing lfa-1
KR20140127234A (ko) 2012-01-27 2014-11-03 에프. 호프만-라 로슈 아게 Ｖｌａ-4 발현 세포로의 표적화된 전달을 위한 인테그린 안타고니스트 접합체
KR20150009952A (ko) 2012-01-27 2015-01-27 에프. 호프만-라 로슈 아게 알파-v-베타-3 발현 세포로의 표적화 전달을 위한 인테그린 안타고니스트 접합체
WO2013126803A1 (en) 2012-02-24 2013-08-29 Protiva Biotherapeutics Inc. Trialkyl cationic lipids and methods of use thereof
CN102600173B (zh) * 2012-03-02 2013-05-29 海南美兰史克制药有限公司 氨氯地平/贝那普利药物组合物脂质体固体制剂
US10322089B2 (en) * 2012-03-14 2019-06-18 The Board Of Trustees Of The Leland Stanford Junior University Nanoparticles, nanoparticle delivery methods, and systems of delivery
WO2013143555A1 (en) * 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
ES2762873T3 (es) 2012-03-29 2020-05-26 Translate Bio Inc Lípidos catiónicos ionizables
EP2830596B1 (en) 2012-03-29 2020-12-30 Translate Bio, Inc. Lipid-derived neutral nanoparticles
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
AU2013243949A1 (en) * 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
AU2013249548A1 (en) 2012-04-19 2014-11-06 Sirna Therapeutics, Inc. Novel diester and triester based low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
WO2013163628A2 (en) 2012-04-27 2013-10-31 Duke University Genetic correction of mutated genes
EP2859102A4 (en) 2012-06-08 2016-05-11 Shire Human Genetic Therapies NUCLEASE RESISTANT POLYNUCLEOTIDES AND USES THEREOF
MX2014015041A (es) 2012-06-08 2015-06-17 Shire Human Genetic Therapies Administración pulmonar de arnm a células objetivo no pulmonares.
US9415109B2 (en) 2012-07-06 2016-08-16 Alnylam Pharmaceuticals, Inc. Stable non-aggregating nucleic acid lipid particle formulations
TW201726600A (zh) 2012-07-06 2017-08-01 協和醱酵麒麟有限公司 陽離子性脂質
WO2014028487A1 (en) 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
EP2885419A4 (en) 2012-08-14 2016-05-25 Moderna Therapeutics Inc ENZYMES AND POLYMERASES FOR RNA SYNTHESIS
CA2892529C (en) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Terminally modified rna
ES2743039T3 (es) 2012-11-29 2020-02-18 Insmed Inc Formulaciones de vancomicina estabilizada
US20150366997A1 (en) 2012-12-07 2015-12-24 Shire Human Genetics Therapies, Inc. COMPOSITIONS AND METHODS FOR mRNA DELIVERY
CA2904151C (en) 2013-03-14 2023-09-12 Shire Human Genetic Therapies, Inc. Cftr mrna compositions and related methods and uses
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
ES2981185T3 (es) 2013-03-14 2024-10-07 Translate Bio Inc Métodos para la purificación de ARN mensajero
LT2970456T (lt) 2013-03-14 2021-08-10 Translate Bio, Inc. Būdai ir kompozicijos, skirti mrnr koduojamų antikūnų pristatymui
US8980864B2 (en) * 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
PL4332576T3 (pl) 2013-03-15 2025-09-08 Translate Bio, Inc. Synergistyczne wzmocnienie dostarczania kwasów nukleinowych poprzez formulacje zmieszane
US9828582B2 (en) 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
WO2014179562A1 (en) 2013-05-01 2014-11-06 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
TW201534578A (zh) 2013-07-08 2015-09-16 Daiichi Sankyo Co Ltd 新穎脂質
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
MX2016005238A (es) 2013-10-22 2016-08-12 Shire Human Genetic Therapies Formulaciones de lipidos para la administracion de acido ribonucleico mensajero.
US20150110857A1 (en) 2013-10-22 2015-04-23 Shire Human Genetic Therapies, Inc. Cns delivery of mrna and uses thereof
BR112016009014B1 (pt) 2013-10-22 2024-02-06 Translate Bio, Inc USO DE COMPOSIÇÃO COMPREENDENDO mRNA PARA DEFICIÊNCIA DE ARGININOSSUCINATO SINTETASE
WO2015061491A1 (en) 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Mrna therapy for phenylketonuria
KR102507624B1 (ko) 2013-11-22 2023-03-09 미나 테라퓨틱스 리미티드 Ｃ/ｅｂｐ 알파 짧은 활성화 ｒｎａ 조성물 및 사용 방법
MX389323B (es) 2013-12-03 2025-03-20 Univ Northwestern Particulas liposomales, metodos para elaborarlas y sus usos.
JP6389477B2 (ja) * 2014-01-09 2018-09-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 カチオン性脂質
US10821175B2 (en) 2014-02-25 2020-11-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
RS58337B1 (sr) 2014-03-24 2019-03-29 Translate Bio Inc Irnk terapija za lečenje očnih oboljenja
DK4023249T3 (da) 2014-04-23 2025-01-13 Modernatx Inc Nukleinsyrevacciner
MX373952B (es) 2014-04-25 2020-07-13 Shire Human Genetic Therapies Métodos de purificación de arn mensajero.
EP3466432B1 (en) 2014-05-15 2020-07-08 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
CN105085295A (zh) * 2014-05-23 2015-11-25 上海交通大学 氨甲环酸的两亲性衍生物及其用途
CN105085292B (zh) * 2014-05-23 2017-12-15 上海交通大学 3‑((2‑(二甲氨基)乙烷基)(甲基)氨基)丙酸的两亲性衍生物及其用途
CN106659731A (zh) 2014-05-30 2017-05-10 夏尔人类遗传性治疗公司 用于递送核酸的可生物降解脂质
US10434064B2 (en) 2014-06-04 2019-10-08 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
UA121863C2 (uk) 2014-06-24 2020-08-10 Транслейт Байо, Інк. Стереохімічно збагачені композиції для доставки нуклеїнових кислот
HRP20221536T1 (hr) * 2014-06-25 2023-02-17 Acuitas Therapeutics Inc. Novi lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina
US10500158B2 (en) 2014-06-30 2019-12-10 Kyowa Hakko Kirin Co., Ltd. Cationic lipid
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
EP3164112A1 (en) 2014-07-02 2017-05-10 Shire Human Genetic Therapies, Inc. Encapsulation of messenger rna
GB201414464D0 (en) 2014-08-14 2014-10-01 Technion Res & Dev Foundation Compositions and methods for therapeutics prescreening
EP3183007B1 (en) 2014-08-19 2020-06-17 Northwestern University Protein/oligonucleotide core-shell nanoparticle therapeutics
DK3185957T3 (da) 2014-08-29 2022-08-29 Alnylam Pharmaceuticals Inc Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
WO2016090262A1 (en) 2014-12-05 2016-06-09 Shire Human Genetic Therapies, Inc. Messenger rna therapy for treatment of articular disease
EP3256487A4 (en) 2015-02-09 2018-07-18 Duke University Compositions and methods for epigenome editing
CA2979695C (en) 2015-03-19 2025-02-06 Translate Bio Inc RNA THERAPY FOR POMPE DISEASE
JP6910947B2 (ja) * 2015-03-24 2021-07-28 協和キリン株式会社 核酸含有脂質ナノ粒子
US10780054B2 (en) 2015-04-17 2020-09-22 Curevac Real Estate Gmbh Lyophilization of RNA
EP3289083A4 (en) 2015-04-27 2018-12-19 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
KR20170141257A (ko) 2015-05-06 2017-12-22 베니텍 바이오파마 리미티드 B형 간염 바이러스 (hbv) 감염의 치료를 위한 시약 및 이의 용도
CN104803863B (zh) * 2015-05-08 2016-07-20 厦门成坤生物技术有限公司 阳离子类脂化合物及其制备方法
US10517827B2 (en) 2015-05-20 2019-12-31 Curevac Ag Dry powder composition comprising long-chain RNA
US10729654B2 (en) 2015-05-20 2020-08-04 Curevac Ag Dry powder composition comprising long-chain RNA
RS64331B1 (sr) 2015-06-19 2023-08-31 Massachusetts Inst Technology Alkenil supstituisani 2,5-piperazindioni i njihova primena u sastavima za isporuku agensa u organizam ili ćeliju subjekta
CA2990202A1 (en) 2015-06-29 2017-01-05 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
BR112018000254A2 (pt) 2015-07-07 2018-09-04 H Lundbeck As inibidores de pde9 com cadeia principal de imidazotriazinona e cadeia principal de imidazopirazinona para o tratamento de doenças periféricas
US20180200186A1 (en) * 2015-07-09 2018-07-19 Insmed Incorporated Compositions and methods for treating lung diseases and lung injury
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
EP4218805A1 (en) 2015-07-21 2023-08-02 ModernaTX, Inc. Infectious disease vaccines
ES2842300T3 (es) 2015-07-31 2021-07-13 Alnylam Pharmaceuticals Inc Composiciones de ARNi de transtiretina (TTR) y métodos para su uso para el tratamiento o la prevención de enfermedades asociadas con TTR
US11564893B2 (en) 2015-08-17 2023-01-31 Modernatx, Inc. Methods for preparing particles and related compositions
WO2017035278A1 (en) 2015-08-24 2017-03-02 Halo-Bio Rnai Therapeutics, Inc. Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
DK3350157T3 (da) 2015-09-17 2022-02-14 Modernatx Inc Forbindelser og sammensætninger til intracellulær afgivelse af terapeutiske midler
IL258476B2 (en) 2015-10-02 2023-04-01 Complexa Inc Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
CA3001003A1 (en) 2015-10-05 2017-04-13 Modernatx, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
EP4089175A1 (en) 2015-10-13 2022-11-16 Duke University Genome engineering with type i crispr systems in eukaryotic cells
CA3001852A1 (en) 2015-10-14 2017-04-20 Translate Bio, Inc. Modification of rna-related enzymes for enhanced production
CN117731769A (zh) 2015-10-22 2024-03-22 摩登纳特斯有限公司 用于水痘带状疱疹病毒(vzv)的核酸疫苗
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
AU2016342376A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Sexually transmitted disease vaccines
MA46316A (fr) 2015-10-22 2021-03-24 Modernatx Inc Vaccin contre le cytomégalovirus humain
MA52645B1 (fr) 2015-10-22 2022-06-30 Modernatx Inc Vaccins contre le virus respiratoire
PT3368507T (pt) 2015-10-28 2023-02-07 Acuitas Therapeutics Inc Novos lípidos e formulações de nanopartículas lipídicas para distribuição de ácidos nucleicos
MX2018005377A (es) 2015-11-30 2018-11-09 Univ Duke Dianas terapeuticas para la correccion del gen de la distrofina humana por edicion genica y metodos de uso.
MD3386484T2 (ro) 2015-12-10 2022-11-30 Modernatx Inc Compoziții și metode de livrare a unor agenți terapeutici
CN106883158B (zh) * 2015-12-15 2019-08-23 中国科学院广州生物医药与健康研究院 生物可降解的氨基脂质类化合物及其制备方法和应用
AU2016377681B2 (en) 2015-12-22 2021-05-13 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
WO2017111172A1 (ja) 2015-12-25 2017-06-29 協和発酵キリン株式会社 カチオン性脂質としての化合物
CN105622473B (zh) * 2016-02-06 2017-07-25 吴国球 一种阳离子氨基脂质及其合成方法和用途
EP3436066A1 (en) 2016-04-01 2019-02-06 Checkmate Pharmaceuticals, Inc. Fc receptor-mediated drug delivery
JP7150608B6 (ja) 2016-04-08 2022-11-11 トランスレイト バイオ， インコーポレイテッド 多量体コード核酸及びその使用
WO2017180915A2 (en) 2016-04-13 2017-10-19 Duke University Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
KR102353847B1 (ko) 2016-04-14 2022-01-21 베니텍 바이오파마 리미티드 안구인두 근이영양증(opmd)의 치료용 시약 및 이의 용도
KR102617833B1 (ko) 2016-05-06 2023-12-27 엑시큐어 오퍼레이팅 컴퍼니 인터류킨 17 수용체 mRNA의 특이적 녹다운을 위한 안티센스 올리고뉴클레오티드 (ASO)를 제시하는 리포좀성 구형 핵산 (SNA) 구축물
CN109414451B (zh) * 2016-05-16 2022-08-12 德克萨斯大学系统董事会 用于作为纳米粒递送tRNA的组合物及其使用方法
US10562849B2 (en) * 2016-05-16 2020-02-18 The Board Of Regents Of The University Of Texas System Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
EP3458034A4 (en) 2016-05-18 2020-01-01 ModernaTX, Inc. POLYNUCLEOTIDES ENCODING RELAXIN
WO2017201342A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
JP2019522047A (ja) 2016-06-13 2019-08-08 トランスレイト バイオ， インコーポレイテッド オルニチントランスカルバミラーゼ欠損症治療のためのメッセンジャーｒｎａ療法
EP3476832B1 (en) 2016-06-24 2023-04-19 Eisai R&D Management Co., Ltd. Cationic lipid
EP3478838A1 (en) * 2016-06-30 2019-05-08 Arbutus Biopharma Corporation Compositions and methods for delivering messenger rna
EP3487523B1 (en) 2016-07-19 2023-09-06 Duke University Therapeutic applications of cpf1-based genome editing
CN109715205A (zh) 2016-08-19 2019-05-03 库瑞瓦格股份公司 用于癌症治疗的rna
WO2018062233A1 (ja) 2016-09-27 2018-04-05 協和発酵キリン株式会社 カチオン性脂質としての化合物
TW201813632A (zh) * 2016-09-28 2018-04-16 日商協和醱酵麒麟有限公司 含有核酸之脂質奈米粒子
WO2018075592A1 (en) 2016-10-21 2018-04-26 Merck Sharp & Dohme Corp. Influenza hemagglutinin protein vaccines
WO2018075980A1 (en) 2016-10-21 2018-04-26 Modernatx, Inc. Human cytomegalovirus vaccine
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
US11400109B2 (en) 2016-11-10 2022-08-02 Translate Bio, Inc. Subcutaneous delivery of messenger RNA
JP7738979B2 (ja) 2016-11-10 2025-09-16 トランスレイト バイオ， インコーポレイテッド Ｍｒｎａ担持脂質ナノ粒子を調製する改善されたプロセス
US10925958B2 (en) 2016-11-11 2021-02-23 Modernatx, Inc. Influenza vaccine
WO2018104538A1 (en) 2016-12-08 2018-06-14 Curevac Ag Rna for treatment or prophylaxis of a liver disease
US11542490B2 (en) 2016-12-08 2023-01-03 CureVac SE RNAs for wound healing
MA50335A (fr) 2016-12-08 2020-08-19 Modernatx Inc Vaccins à acide nucléique contre des virus respiratoires
EP3558356A2 (en) 2016-12-23 2019-10-30 CureVac AG Mers coronavirus vaccine
EP3558355A2 (en) 2016-12-23 2019-10-30 CureVac AG Henipavirus vaccine
EP3558354A1 (en) 2016-12-23 2019-10-30 CureVac AG Lassa virus vaccine
FI3565891T3 (fi) 2017-01-09 2023-07-04 Whitehead Inst Biomedical Res Menetelmiä geeniekspression muuttamiseksi häiritsemällä säätelysilmukoita muodostavia transkriptiotekijämultimeerejä
US11241490B2 (en) 2017-01-11 2022-02-08 The Trustees Of The University Of Pennsylvania Nucleoside-modified RNA for inducing an immune response against zika virus
MA47515A (fr) 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes
MX2019010155A (es) 2017-02-27 2020-12-10 Translate Bio Inc Arnm de cftr optimizado por codón novedoso.
WO2018165257A1 (en) 2017-03-07 2018-09-13 Translate Bio, Inc. Polyanionic delivery of nucleic acids
ES2911186T3 (es) 2017-03-15 2022-05-18 Modernatx Inc Formas cristalinas de aminolípidos
CA3055653A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. Respiratory syncytial virus vaccine
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
AU2018234692B2 (en) 2017-03-15 2022-06-02 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
US20200030432A1 (en) 2017-03-17 2020-01-30 Modernatx, Inc. Zoonotic disease rna vaccines
CN110392577A (zh) 2017-03-17 2019-10-29 库尔维科公司 用于组合抗癌疗法的rna疫苗和免疫检查点抑制剂
US11739335B2 (en) 2017-03-24 2023-08-29 CureVac SE Nucleic acids encoding CRISPR-associated proteins and uses thereof
US11357856B2 (en) 2017-04-13 2022-06-14 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
EP3618859A4 (en) 2017-04-27 2021-05-05 Vanderbilt University HEPATITIS C VIRUS GENE SEQUENCES AND METHODS OF USE
US11820728B2 (en) 2017-04-28 2023-11-21 Acuitas Therapeutics, Inc. Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
MA49138A (fr) 2017-05-16 2020-03-25 Translate Bio Inc Traitement de la fibrose kystique par administration d'arnm à codons optimisés codant pour la cftr
EP3630985B1 (en) 2017-05-31 2025-08-27 Arcturus Therapeutics, Inc. Synthesis and structure of high potency rna therapeutics
EP3630200A4 (en) 2017-05-31 2021-02-24 Arcturus Therapeutics, Inc. THERAPEUTICS FOR PHENYLKETONURIA
WO2018222926A1 (en) 2017-05-31 2018-12-06 Ultragenyx Pharmaceutical Inc. Therapeutics for glycogen storage disease type iii
WO2018232120A1 (en) 2017-06-14 2018-12-20 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
EP3641834B1 (en) 2017-06-19 2023-10-04 Translate Bio, Inc. Messenger rna therapy for the treatment of friedreich's ataxia
US10988754B2 (en) 2017-07-04 2021-04-27 Cure Vac AG Nucleic acid molecules
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
CA3071968A1 (en) 2017-08-04 2019-02-07 Kyowa Kirin Co., Ltd. Nucleic acid-containing lipid nanoparticle
EP3668833A1 (en) 2017-08-16 2020-06-24 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019036000A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
WO2019036030A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
US11542225B2 (en) 2017-08-17 2023-01-03 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
EP3673069A1 (en) 2017-08-22 2020-07-01 CureVac AG Bunyavirales vaccine
MX2020002348A (es) 2017-08-31 2020-10-08 Modernatx Inc Métodos de elaboración de nanopartículas lipídicas.
AU2018330495A1 (en) 2017-09-08 2020-03-26 Mina Therapeutics Limited Stabilized hnf4a sarna compositions and methods of use
EP3679140B1 (en) 2017-09-08 2022-11-16 MiNA Therapeutics Limited Stabilized cebpa sarna compositions and methods of use
MA50253A (fr) 2017-09-14 2020-07-22 Modernatx Inc Vaccins à arn contre le virus zika
MA50267A (fr) 2017-09-19 2020-07-29 Alnylam Pharmaceuticals Inc Compositions et méthodes de traitement de l'amylose médiée par la transthyrétine (ttr)
IL321714A (en) 2017-10-19 2025-08-01 CureVac SE Novel artificial nucleic acid molecules
JP2021502079A (ja) 2017-11-08 2021-01-28 キュアバック アーゲー ＲＮＡ配列の適合（Ａｄａｐｔａｔｉｏｎ）
EP3723796A1 (en) 2017-12-13 2020-10-21 CureVac AG Flavivirus vaccine
CA3084061A1 (en) 2017-12-20 2019-06-27 Translate Bio, Inc. Improved composition and methods for treatment of ornithine transcarbamylase deficiency
TWI894123B (zh) 2017-12-27 2025-08-21 日商武田藥品工業有限公司 含核酸之脂質奈米粒子及其用途
EP3733647B1 (en) 2017-12-27 2022-06-15 Eisai R&D Management Co., Ltd. Cationic lipid
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
BR112020015308A8 (pt) 2018-01-29 2023-02-07 Merck Sharp & Dohme Proteínas f de rsv estabilizadas e usos das mesmas
WO2019152802A1 (en) 2018-02-02 2019-08-08 Translate Bio, Inc. Cationic polymers
US20210038732A1 (en) * 2018-02-12 2021-02-11 Interna Technologies B.V. Anticancer microrna and lipid formulations thereof
EP3752194A4 (en) 2018-02-13 2022-03-16 Checkmate Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR TUMOR IMMUNOTHERAPY
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
WO2019193183A2 (en) 2018-04-05 2019-10-10 Curevac Ag Novel yellow fever nucleic acid molecules for vaccination
EP3775218A1 (en) 2018-04-09 2021-02-17 Checkmate Pharmaceuticals Packaging oligonucleotides into virus-like particles
US11566246B2 (en) 2018-04-12 2023-01-31 Mina Therapeutics Limited SIRT1-saRNA compositions and methods of use
EP4227319B1 (en) 2018-04-17 2025-11-26 CureVac SE Novel rsv rna molecules and compositions for vaccination
JP7448488B2 (ja) 2018-05-15 2024-03-12 トランスレイト バイオ， インコーポレイテッド メッセンジャーｒｎａの皮下送達
AU2019271215B2 (en) 2018-05-16 2024-09-12 Translate Bio, Inc. Ribose cationic lipids
JP7488193B2 (ja) 2018-05-24 2024-05-21 トランスレイト バイオ， インコーポレイテッド チオエステルカチオン性脂質
HUE065709T2 (hu) 2018-05-25 2024-06-28 Cardurion Pharmaceuticals Inc 6-[(3S,4S)-4-metil-1-(pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetrahidropirán-4-il-7H-imidazo[1,5-a] pirazin-8-on vegyület monohidrát és kristályos formái
MA52762A (fr) 2018-05-30 2021-04-14 Translate Bio Inc Lipides cationiques comprenant une fraction stéroïdienne
JP2021525743A (ja) 2018-05-30 2021-09-27 トランスレイト バイオ， インコーポレイテッド リン酸エステルカチオン性脂質
MA52766A (fr) 2018-05-30 2021-04-14 Translate Bio Inc Lipides cationiques vitaminiques
CN112384205B (zh) 2018-05-30 2024-05-03 川斯勒佰尔公司 信使rna疫苗及其用途
US20210260178A1 (en) 2018-06-27 2021-08-26 Curevac Ag Novel lassa virus rna molecules and compositions for vaccination
CN120514877A (zh) 2018-07-23 2025-08-22 川斯勒佰尔公司 信使rna的干粉制剂
WO2020041793A1 (en) 2018-08-24 2020-02-27 Translate Bio, Inc. Methods for purification of messenger rna
CA3108920A1 (en) 2018-08-29 2020-03-05 Translate Bio, Inc. Improved process of preparing mrna-loaded lipid nanoparticles
MA53501A (fr) 2018-08-31 2021-07-07 Imara Inc Inhibiteurs de pde9 pour le traitement de la drépanocytose
US20230145188A1 (en) 2018-09-14 2023-05-11 Translate Bio, Inc. Composition and methods for treatment of methylmalonic acidemia
EP4509118A3 (en) 2018-09-19 2025-05-14 ModernaTX, Inc. High-purity peg lipids and uses thereof
CA3113025A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Peg lipids and uses thereof
US12263248B2 (en) 2018-09-19 2025-04-01 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
EP3852911B1 (en) 2018-09-21 2025-01-22 Acuitas Therapeutics, Inc. Systems and methods for manufacturing lipid nanoparticles and liposomes
JP7387745B2 (ja) 2018-10-01 2023-11-28 アルニラム・ファーマシューティカルズ・インコーポレーテッド 活性物質の送達のための生分解性脂質
KR20210093232A (ko) 2018-10-09 2021-07-27 더 유니버시티 오브 브리티시 콜롬비아 유기용매와 세제가 없는 형질감염 적격 소포를 포함하는 조성물과 시스템 및 관련 방법
MX2021004357A (es) 2018-10-18 2021-05-31 Takeda Pharmaceuticals Co Metodo para la activacion y proliferacion de las celulas t.
AU2019362031A1 (en) 2018-10-19 2021-04-08 Translate Bio, Inc. Pumpless encapsulation of messenger RNA
MX2021005482A (es) 2018-11-09 2021-09-08 Translate Bio Inc Lípidos de 2,5-dioxopiperazina con porciones éster, tioéster, disulfuro y anhidrido intercaladas.
EA202191315A1 (ru) 2018-11-09 2021-09-08 Арбутус Биофарма Корпорэйшн Катионные липиды, содержащие кремний
WO2020097376A1 (en) 2018-11-09 2020-05-14 Translate Bio, Inc. Multi-peg lipid compounds
WO2020097379A2 (en) 2018-11-09 2020-05-14 Translate Bio, Inc. Peg lipidoid compounds
WO2020097511A2 (en) 2018-11-09 2020-05-14 Translate Bio, Inc. Messenger rna therapy for treatment of ocular diseases
AU2019378763B2 (en) 2018-11-12 2025-06-26 Translate Bio, Inc. Methods for inducing immune tolerance
AU2019383413A1 (en) 2018-11-21 2021-05-27 Translate Bio, Inc. Cationic lipid compounds and compositions thereof for use in the delivery of messenger RNA
AU2019384557B2 (en) 2018-11-21 2025-07-17 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR
AU2019394996B2 (en) 2018-12-06 2025-11-06 Arcturus Therapeutics, Inc. Compositions and methods for treating ornithine transcarbamylase deficiency
TW202039534A (zh) 2018-12-14 2020-11-01 美商美國禮來大藥廠 KRAS變體mRNA分子
EP3897702A2 (en) 2018-12-21 2021-10-27 CureVac AG Rna for malaria vaccines
CN113412273B (zh) 2019-01-07 2025-08-22 川斯勒佰尔公司 用于治疗原发性纤毛运动障碍的组合物和方法
US11453639B2 (en) 2019-01-11 2022-09-27 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
BR112021014845A2 (pt) * 2019-01-31 2021-11-03 Modernatx Inc Métodos de preparação de nanopartículas lipídicas
WO2020161342A1 (en) 2019-02-08 2020-08-13 Curevac Ag Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih
WO2020206231A1 (en) 2019-04-05 2020-10-08 Precision Biosciences, Inc. Methods of preparing populations of genetically-modified immune cells
WO2020208361A1 (en) 2019-04-12 2020-10-15 Mina Therapeutics Limited Sirt1-sarna compositions and methods of use
EP3956303A1 (en) 2019-04-18 2022-02-23 Translate Bio, Inc. Cystine cationic lipids
EP3959195B1 (en) 2019-04-22 2023-11-08 Translate Bio, Inc. Thioester cationic lipids
EP3962902A1 (en) 2019-05-03 2022-03-09 Translate Bio, Inc. Di-thioester cationic lipids
WO2020232276A1 (en) 2019-05-14 2020-11-19 Translate Bio, Inc. Improved process of preparing mrna-loaded lipid nanoparticles
IL288284B2 (en) 2019-05-22 2024-06-01 Massachusetts Inst Technology Circular rna compositions and methods
EP3976593A1 (en) 2019-05-31 2022-04-06 Translate Bio, Inc. Macrocyclic lipids
WO2020254535A1 (en) 2019-06-18 2020-12-24 Curevac Ag Rotavirus mrna vaccine
CN114401942B (zh) 2019-06-21 2024-01-26 川斯勒佰尔公司 三(羟甲基)甲基甘氨酸和柠檬酸脂质
WO2020257611A1 (en) 2019-06-21 2020-12-24 Translate Bio, Inc. Cationic lipids comprising an hydroxy moiety
WO2021003462A1 (en) * 2019-07-03 2021-01-07 Factor Bioscience Inc. Cationic lipids and uses thereof
EP4467653A3 (en) 2019-07-08 2024-12-18 Translate Bio, Inc. Improved mrna-loaded lipid nanoparticles and processes of making the same
EP3999642A1 (en) 2019-07-19 2022-05-25 Flagship Pioneering Innovations VI, LLC Recombinase compositions and methods of use
KR20220038365A (ko) 2019-07-23 2022-03-28 트랜슬레이트 바이오 인코포레이티드 Mrna-로딩된 지질 나노입자의 안정한 조성물 및 제조 방법
JP7630904B2 (ja) * 2019-07-23 2025-02-18 株式会社東芝 核酸導入キャリア、核酸導入キャリアセット、核酸導入組成物及び核酸導入方法
AU2020322014A1 (en) 2019-07-30 2022-02-24 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
US20220296628A1 (en) 2019-08-14 2022-09-22 Curevac Ag Rna combinations and compositions with decreased immunostimulatory properties
CA3154618A1 (en) 2019-09-19 2021-03-25 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
WO2021055609A1 (en) 2019-09-20 2021-03-25 Translate Bio, Inc. Mrna encoding engineered cftr
US11987791B2 (en) 2019-09-23 2024-05-21 Omega Therapeutics, Inc. Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (HNF4α) gene expression
CN114391040A (zh) 2019-09-23 2022-04-22 欧米茄治疗公司 用于调节载脂蛋白b(apob)基因表达的组合物和方法
JP7650873B2 (ja) 2019-10-09 2025-03-25 トランスレイト バイオ， インコーポレイテッド メッセンジャーｒｎａの組成物、方法および使用
US20220396556A1 (en) * 2019-10-18 2022-12-15 The Trustees Of The University Of Pennsylvania Lipid and Lipid Nanoparticle Formulation for Drug Delivery
JP2022553042A (ja) 2019-10-21 2022-12-21 トランスレイト バイオ， インコーポレイテッド メッセンジャーｒｎａの組成物、方法および使用
JP2023504568A (ja) 2019-12-04 2023-02-03 オルナ セラピューティクス インコーポレイテッド 環状ｒｎａ組成物及び方法
WO2021127394A2 (en) 2019-12-20 2021-06-24 Translate Bio, Inc. Rectal delivery of messenger rna
CN115461042A (zh) 2019-12-20 2022-12-09 翻译生物公司 制备负载mrna的脂质纳米颗粒的改进方法
AU2020407285A1 (en) 2019-12-20 2022-08-11 CureVac SE Lipid nanoparticles for delivery of nucleic acids
WO2021142245A1 (en) 2020-01-10 2021-07-15 Translate Bio, Inc. Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
KR20220144416A (ko) 2020-02-04 2022-10-26 큐어백 아게 코로나바이러스 백신
US11638754B2 (en) 2020-02-14 2023-05-02 Merck Sharp & Dohme Llc HPV vaccine
WO2021173840A1 (en) 2020-02-25 2021-09-02 Translate Bio, Inc. Improved processes of preparing mrna-loaded lipid nanoparticles
WO2021178510A1 (en) 2020-03-03 2021-09-10 Arcturus Therapeutics, Inc. Compositions and methods for the treatment of ornithine transcarbamylase deficiency
AU2021233816A1 (en) 2020-03-09 2022-10-06 Arcturus Therapeutics, Inc. Coronavirus vaccine compositions and methods
CN116096886A (zh) 2020-03-11 2023-05-09 欧米茄治疗公司 用于调节叉头框p3(foxp3)基因表达的组合物和方法
JP2023520764A (ja) 2020-03-24 2023-05-19 ジェネレーション バイオ カンパニー 第ｉｘ因子治療薬を発現するための非ウイルス性ｄｎａベクター及びその使用
MX2022011806A (es) 2020-03-24 2023-01-11 Generation Bio Co Vectores de adn no virales y usos de estos para expresar agentes terapéuticos contra gaucher.
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
AU2021252164A1 (en) 2020-04-09 2022-12-15 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
JP2023524071A (ja) 2020-05-01 2023-06-08 アークトゥラス・セラピューティクス・インコーポレイテッド 嚢胞性線維症を治療するための核酸及び方法
EP4146342A1 (en) 2020-05-07 2023-03-15 Translate Bio, Inc. Improved compositions for cftr mrna therapy
EP4146680A1 (en) 2020-05-07 2023-03-15 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
AU2021269042A1 (en) 2020-05-07 2023-02-02 Translate Bio, Inc. Optimized nucleotide sequences encoding SARS-CoV-2 antigens
WO2021231697A1 (en) 2020-05-14 2021-11-18 Translate Bio, Inc. Peg lipidoid compounds
AU2021273502A1 (en) 2020-05-15 2023-02-02 Translate Bio, Inc. Lipid nanoparticle formulations for mRNA delivery
JP2023527309A (ja) 2020-05-19 2023-06-28 オルナ セラピューティクス インコーポレイテッド 環状ｒｎａ組成物及び方法
IL298362A (en) 2020-05-20 2023-01-01 Flagship Pioneering Innovations Vi Llc Coronavirus antigen compositions and their uses
AU2021275213A1 (en) 2020-05-20 2023-02-02 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
AU2021281453A1 (en) 2020-05-29 2022-11-17 Flagship Pioneering Innovations Vi, Llc. Trem compositions and methods relating thereto
MX2022015132A (es) 2020-05-29 2023-03-08 CureVac SE Vacunas combinadas a base de acidos nucleicos.
CA3180101A1 (en) 2020-05-29 2021-12-02 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods relating thereto
US20240307556A1 (en) 2020-07-02 2024-09-19 Maritime Therapeutics, Inc. Compositions and methods for reverse gene therapy
PH12023550030A1 (en) 2020-07-08 2024-03-11 Janssen Sciences Ireland Unlimited Co Rna replicon vaccines against hbv
MX2023000614A (es) 2020-07-16 2023-02-13 Acuitas Therapeutics Inc Lipidos cationicos para usarse en nanoparticulas lipidicas.
WO2022023284A1 (en) 2020-07-27 2022-02-03 Anjarium Biosciences Ag Compositions of dna molecules, methods of making therefor, and methods of use thereof
CA3170741A1 (en) 2020-07-31 2022-02-03 Curevac Ag Nucleic acid encoded antibody mixtures
KR20230167008A (ko) * 2020-08-06 2023-12-07 모더나티엑스, 인크. 지질 나노입자의 제조 방법
BR112023002642A2 (pt) 2020-08-14 2023-04-04 Arcturus Therapeutics Inc Método para liofilizar nanopartículas lipídicas
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
US20240066114A1 (en) 2020-08-31 2024-02-29 CureVac SE Multivalent nucleic acid based coronavirus vaccines
WO2022051629A1 (en) 2020-09-03 2022-03-10 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
JP2023544197A (ja) 2020-10-06 2023-10-20 トランスレイト バイオ， インコーポレイテッド 脂質ナノ粒子の改善された方法および製剤
US20230365995A1 (en) 2020-10-07 2023-11-16 Precision Biosciences, Inc. Lipid nanoparticle compositions
AU2021361986A1 (en) 2020-10-12 2023-06-15 Translate Bio, Inc. Improved process of preparing mrna-loaded lipid nanoparticles
WO2022081548A1 (en) 2020-10-12 2022-04-21 Translate Bio, Inc. Improved process of preparing ice-based lipid nanoparticles
US20220218622A1 (en) 2020-10-14 2022-07-14 George Mason Research Foundation, Inc. Ionizable lipids and methods of manufacture and use thereof
EP4240326A1 (en) 2020-11-09 2023-09-13 Translate Bio, Inc. Improved compositions for delivery of codon-optimized mrna
US11591544B2 (en) 2020-11-25 2023-02-28 Akagera Medicines, Inc. Ionizable cationic lipids
IL303165A (en) 2020-11-25 2023-07-01 Translate Bio Inc Stable liquid lipid nanoparticle formulations
PH12023500013A1 (en) 2020-12-04 2024-03-11 Tidal Therapeutics Inc Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
GB2603454A (en) 2020-12-09 2022-08-10 Ucl Business Ltd Novel therapeutics for the treatment of neurodegenerative disorders
US20240299309A1 (en) 2020-12-22 2024-09-12 CureVac SE Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
JP2024501288A (ja) 2020-12-23 2024-01-11 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー 修飾ｔｒｅｍの組成物及びその使用
EP4267740A1 (en) 2020-12-28 2023-11-01 Arcturus Therapeutics, Inc. Transcription activator-like effector nucleases (talens) targeting hbv
WO2022155404A1 (en) 2021-01-14 2022-07-21 Translate Bio, Inc. Methods and compositions for delivering mrna coded antibodies
WO2022162027A2 (en) 2021-01-27 2022-08-04 Curevac Ag Method of reducing the immunostimulatory properties of in vitro transcribed rna
TW202245835A (zh) 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
US20250268994A1 (en) 2021-03-25 2025-08-28 Translate Bio, Inc. Optimized Nucleotide Sequences Encoding the Extracellular Domain of Human ACE2 Protein or a Portion Thereof
EP4314292A1 (en) 2021-03-26 2024-02-07 MiNA Therapeutics Limited Tmem173 sarna compositions and methods of use
CA3212653A1 (en) 2021-03-26 2022-09-29 Glaxosmithkline Biologicals Sa Immunogenic compositions
WO2022207862A2 (en) 2021-03-31 2022-10-06 Curevac Ag Syringes containing pharmaceutical compositions comprising rna
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
WO2022225918A1 (en) 2021-04-19 2022-10-27 Translate Bio, Inc. Improved compositions for delivery of mrna
AU2022260111A1 (en) 2021-04-20 2023-11-30 Anjarium Biosciences Ag Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof
AU2022264509A1 (en) 2021-04-27 2023-12-14 Generation Bio Co. Non-viral dna vectors expressing therapeutic antibodies and uses thereof
EP4329884A1 (en) 2021-04-27 2024-03-06 Generation Bio Co. Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
WO2022233880A1 (en) 2021-05-03 2022-11-10 Curevac Ag Improved nucleic acid sequence for cell type specific expression
EP4347577A4 (en) * 2021-05-28 2025-09-03 Nanovation Therapeutics Inc KC2-TYPE LIPIDS
US20240269302A1 (en) 2021-06-11 2024-08-15 Nibec Co., Ltd. Nanoparticle comprising peptide-lipid conjugate for delivering oligonucleotide into target cell and pharmaceutical composition comprising same
EP4362957A1 (en) 2021-07-01 2024-05-08 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and related methods
JP2024527541A (ja) 2021-07-01 2024-07-25 トランスレイト バイオ， インコーポレイテッド Ｍｒｎａの送達のための組成物
WO2023283359A2 (en) 2021-07-07 2023-01-12 Omega Therapeutics, Inc. Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
EP4377457A1 (en) 2021-07-26 2024-06-05 Flagship Pioneering Innovations VI, LLC Trem compositions and uses thereof
US20240342206A1 (en) 2021-07-30 2024-10-17 CureVac SE mRNAS FOR TREATMENT OR PROPHYLAXIS OF LIVER DISEASES
US20240254483A1 (en) 2021-07-30 2024-08-01 Tune Therapeutics, Inc. Compositions and methods for modulating expression of frataxin (fxn)
CA3227105A1 (en) 2021-07-30 2023-02-02 Tune Therapeutics, Inc. Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
MX2024001194A (es) 2021-08-03 2024-02-27 Alnylam Pharmaceuticals Inc Composiciones de acido ribonucleico de interferencia (arni) de transtiretina (ttr) y sus metodos de uso.
MX2024002144A (es) 2021-08-19 2024-04-23 Merck Sharp & Dohme Llc Nueva nanoparticula lipidica termostable y metodos de uso de la misma.
CN113461577B (zh) * 2021-09-01 2021-12-14 中山大学附属第七医院(深圳) 一种氨基脂质及其应用
CN115745942B (zh) * 2021-09-03 2025-06-10 广州谷森制药有限公司 阳离子脂质化合物
CN115745941B (zh) * 2021-09-03 2025-07-01 广州谷森制药有限公司 阳离子脂质化合物
AU2022336664A1 (en) 2021-09-03 2024-01-18 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
AU2022336209B2 (en) 2021-09-03 2025-10-16 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
CN115772089B (zh) * 2021-09-07 2025-06-10 广州谷森制药有限公司 阳离子脂质化合物
EP4271818B1 (en) 2021-09-17 2024-07-31 Flagship Pioneering Innovations VI, LLC Compositions and methods for producing circular polyribonucleotides
TW202322826A (zh) 2021-10-18 2023-06-16 美商旗艦先鋒創新有限責任公司 用於純化多核糖核苷酸之組成物及方法
US20250027108A1 (en) 2021-10-29 2025-01-23 CureVac SE Improved circular rna for expressing therapeutic proteins
WO2023081526A1 (en) 2021-11-08 2023-05-11 Orna Therapeutics, Inc. Lipid nanoparticle compositions for delivering circular polynucleotides
CN118591398A (zh) 2021-11-10 2024-09-03 翻译生物公司 用于治疗原发性纤毛运动不良症的组合物和方法
US20250352638A1 (en) 2021-11-24 2025-11-20 Flagship Pioneering Innovations Vi, Llc Coronavirus immunogen compositions and their uses
MX2024006440A (es) 2021-11-24 2024-08-19 Flagship Pioneering Innovations Vi Llc Composiciones inmunogenicas y sus usos.
CA3238370A1 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovations Vi, Llc Varicella-zoster virus immunogen compositions and their uses
WO2023099884A1 (en) 2021-12-01 2023-06-08 Mina Therapeutics Limited Pax6 sarna compositions and methods of use
GB202117758D0 (en) 2021-12-09 2022-01-26 Ucl Business Ltd Therapeutics for the treatment of neurodegenerative disorders
IL313486A (en) 2021-12-16 2024-08-01 Acuitas Therapeutics Inc Lipids for use in lipid nanoparticle formulations
WO2023115013A1 (en) 2021-12-17 2023-06-22 Flagship Pioneering Innovations Vi, Llc Methods for enrichment of circular rna under denaturing conditions
JP2025500360A (ja) 2021-12-22 2025-01-09 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー ポリリボヌクレオチドを精製するための組成物及び方法
IL313714A (en) 2021-12-23 2024-08-01 Flagship Pioneering Innovations Vi Llc Cyclic polyribonucleotides encoding antifusogenic polypeptides
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023135273A2 (en) 2022-01-14 2023-07-20 Anjarium Biosciences Ag Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
WO2023144193A1 (en) 2022-01-25 2023-08-03 CureVac SE Mrnas for treatment of hereditary tyrosinemia type i
US20250099614A1 (en) 2022-01-28 2025-03-27 CureVac SE Nucleic acid encoded transcription factor inhibitors
US20250144235A1 (en) 2022-02-02 2025-05-08 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023170435A1 (en) 2022-03-07 2023-09-14 Mina Therapeutics Limited Il10 sarna compositions and methods of use
KR20240161965A (ko) 2022-03-14 2024-11-13 제너레이션 바이오 컴퍼니 이종 프라임 부스트 백신 조성물 및 사용 방법
CN119072464A (zh) 2022-03-25 2024-12-03 赛欧生物医药股份有限公司 新型可电离脂质和脂质纳米颗粒以及其使用方法
CN119136789A (zh) * 2022-03-28 2024-12-13 日油株式会社 包封核酸的脂质纳米粒子的制造方法和包括该制造方法的药物组合物的制造方法，以及将核酸导入细胞内或靶细胞内的方法
CA3255116A1 (en) 2022-04-01 2023-10-05 Nanovation Therapeutics Inc METHOD FOR ADMINISTRATING RNA AND ASSOCIATED COMPOSITION
JP2025511756A (ja) 2022-04-08 2025-04-16 フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー ワクチン及び関連する方法
CN119563108A (zh) 2022-05-01 2025-03-04 耶达研究发展公司 用于减轻癌症相关恶病质的hnf4a的重表达
WO2023220083A1 (en) 2022-05-09 2023-11-16 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods of use for treating proliferative disorders
EP4522753A2 (en) 2022-05-13 2025-03-19 Flagship Pioneering Innovations VII, LLC Double stranded dna compositions and related methods
WO2023218420A1 (en) 2022-05-13 2023-11-16 Janssen Pharmaceuticals, Inc. Mrna compositions for inducing latent hiv-1 reversal
AU2023274371A1 (en) 2022-05-25 2024-10-31 CureVac SE Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
AU2023275780A1 (en) 2022-05-25 2024-12-05 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
EP4536197A1 (en) 2022-06-07 2025-04-16 Generation Bio Co. Lipid nanoparticle compositions and uses thereof
WO2023240156A1 (en) 2022-06-08 2023-12-14 Tidal Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
EP4544043A1 (en) 2022-06-22 2025-04-30 Flagship Pioneering Innovations VI, LLC Compositions of modified trems and uses thereof
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
WO2023250511A2 (en) 2022-06-24 2023-12-28 Tune Therapeutics, Inc. Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
CA3259982A1 (en) 2022-06-30 2024-01-04 Indapta Therapeutics Inc COMBINATION OF MODIFIED NATURAL KILLER (NK) CELLS AND ANTIBODY THERAPY AND ASSOCIATED METHODS
CA3261865A1 (en) 2022-07-12 2024-01-18 Tune Therapeutics Inc TARGETED TRANSCRIPTIONAL ACTIVATION COMPOSITIONS, SYSTEMS AND METHODS
CN120129693A (zh) 2022-08-01 2025-06-10 旗舰创业创新第七有限责任公司 免疫调节蛋白及相关方法
EP4569112A1 (en) 2022-08-12 2025-06-18 Remix Therapeutics Inc. Methods and compositions for modulating splicing at alternative splice sites
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024040222A1 (en) 2022-08-19 2024-02-22 Generation Bio Co. Cleavable closed-ended dna (cedna) and methods of use thereof
CA3264214A1 (en) 2022-08-19 2024-02-22 Tune Therapeutics Inc Compositions, systems and methods of regulating the hepatitis B virus by targeted gene suppression
EP4581012A2 (en) 2022-08-31 2025-07-09 Sail Biomedicines, Inc. Novel ionizable lipids and lipid nanoparticles and methods of using the same
WO2024053648A1 (ja) 2022-09-06 2024-03-14 国立大学法人九州大学 脂質ナノ粒子
CN120239746A (zh) 2022-09-19 2025-07-01 图恩疗法股份有限公司 用于调节t细胞功能的组合物、系统和方法
WO2024068545A1 (en) 2022-09-26 2024-04-04 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
CA3266203A1 (en) * 2022-10-25 2024-05-02 Nanovation Therapeutics Inc LIPID NANOPARTICLE FORMULATIONS FOR ADMINISTRATION OF ANTISENSE OLIGONUCLEOTIDES
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
AU2023372397A1 (en) 2022-10-31 2025-05-08 Flagship Pioneering Innovations Vi, Llc Compositions and methods for purifying polyribonucleotides
TW202425959A (zh) 2022-11-08 2024-07-01 美商歐納醫療公司 遞送多核苷酸的脂質及奈米顆粒組合物
EP4615465A1 (en) 2022-11-08 2025-09-17 Flagship Pioneering Innovations VI, LLC Compositions and methods for producing circular polyribonucleotides
TW202428289A (zh) 2022-11-08 2024-07-16 美商歐納醫療公司 環狀rna組合物
WO2024102762A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
CN120265279A (zh) 2022-11-21 2025-07-04 翻译生物公司 信使rna的干粉配制品的组合物及其使用方法
EP4626401A1 (en) 2022-12-01 2025-10-08 Generation Bio Co. Stealth lipid nanoparticle compositions for cell targeting
EP4626402A1 (en) 2022-12-01 2025-10-08 Generation Bio Co. Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
AU2023406321A1 (en) 2022-12-01 2025-05-29 Generation Bio Co. Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
AU2023406303A1 (en) 2022-12-01 2025-05-29 Generation Bio Co. Lipid nanoparticles comprising nucleic acids, ionizable lipids, sterols, lipid anchored polymers and helper lipids, their uses
EP4630561A1 (en) 2022-12-09 2025-10-15 Takeda Pharmaceutical Company Limited Modified immunomodulators
EP4631528A1 (en) 2022-12-09 2025-10-15 Nibec Co., Ltd. Nanoparticle comprising peptide-based conjugate for delivering oligonucleotide into target cell and pharmaceutical composition comprising same
WO2024123134A1 (ko) 2022-12-09 2024-06-13 서울대학교산학협력단 B 세포 및 t 세포 내로 mrna를 전달하기 위한 펩타이드 기반 결합체를 포함하는 나노입자 및 이의 용도
TW202430215A (zh) 2022-12-14 2024-08-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 用於將治療劑遞送至骨之組成物和方法
EP4634388A1 (en) 2022-12-14 2025-10-22 Providence Therapeutics Holdings Inc. Compositions and methods for infectious diseases
AU2023398825A1 (en) 2022-12-15 2025-06-26 Orna Therapeutics, Inc. Circular rna compositions and methods
AU2023394992A1 (en) 2022-12-15 2025-07-31 Sanofi Pasteur Inc. Mrna encoding influenza virus-like particle
CN120475991A (zh) 2022-12-20 2025-08-12 赛诺菲巴斯德有限公司 鼻病毒mRNA疫苗
WO2024134199A1 (en) 2022-12-22 2024-06-27 Mina Therapeutics Limited Chemically modified sarna compositions and methods of use
EP4642481A2 (en) 2022-12-29 2025-11-05 Popvax Private Limited Multitarget vaccines and therapeutics
WO2024141784A2 (en) 2022-12-29 2024-07-04 Popvax Private Limited Broadly protective betacoronavirus vaccines and compositions
US12410394B2 (en) * 2023-01-06 2025-09-09 Athergen, Inc. Composition comprising nicotinamide mononucleotide and leucomethylene blue
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
US20240252520A1 (en) 2023-01-09 2024-08-01 Beth Israel Deaconess Medical Center, Inc. Therapeutic agents and their use for treating chronic wounds
TW202438673A (zh) 2023-01-09 2024-10-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 疫苗及相關方法
WO2024151673A2 (en) 2023-01-09 2024-07-18 President And Fellows Of Harvard College Recombinant nucleic acid molecules and their use in wound healing
WO2024163683A2 (en) 2023-02-01 2024-08-08 Tune Therapeutics, Inc. Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
WO2024163678A2 (en) 2023-02-01 2024-08-08 Tune Therapeutics, Inc. Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
TW202448516A (zh) 2023-02-03 2024-12-16 美商健臻公司 接合hsc特異性抗體的脂質奈米粒子及其用途
EP4658239A1 (en) 2023-02-03 2025-12-10 GlaxoSmithKline Biologicals S.A. Rna formulation
TW202438515A (zh) 2023-02-06 2024-10-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 免疫調節組合物及相關方法
AU2024218499A1 (en) * 2023-02-09 2025-08-14 Seqirus Inc. Ionizable cationic compound
US20240293318A1 (en) 2023-02-13 2024-09-05 Flagship Pioneering Innovations Vii, Llc Cleavable linker-containing ionizable lipids and lipid carriers for therapeutic compositions
GB202302092D0 (en) 2023-02-14 2023-03-29 Glaxosmithkline Biologicals Sa Analytical method
IL322201A (en) 2023-02-17 2025-09-01 Flagship Pioneering Innovations Vii Llc DNA structures containing modified uracil
US20240293582A1 (en) 2023-02-17 2024-09-05 Flagship Pioneering Innovations Vii, Llc Dna compositions comprising modified cytosine
AU2024233180A1 (en) 2023-03-08 2025-09-25 CureVac SE Novel lipid nanoparticle formulations for delivery of nucleic acids
WO2024192422A1 (en) 2023-03-15 2024-09-19 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
KR20250162610A (ko) 2023-03-15 2025-11-18 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 폴리리보뉴클레오티드를 포함하는 조성물 및 이의 용도
WO2024205657A2 (en) 2023-03-29 2024-10-03 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
WO2024200826A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell inhibiting molecule and use thereof
WO2024200823A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
AR132276A1 (es) 2023-04-07 2025-06-11 Takeda Pharmaceuticals Co Complejo de conjugación
AU2024252590A1 (en) 2023-04-12 2025-10-23 Flagship Pioneering Innovations Vi, Llc Trems for use in correction of missense mutations
AU2024255972A1 (en) 2023-04-12 2025-10-23 Flagship Pioneering Innovations Vi, Llc Modified trems, compositions, and related methods thereof
CN120957707A (zh) 2023-04-17 2025-11-14 赛诺菲巴斯德有限公司 可复溶干粉配制品及其使用方法
WO2024220746A2 (en) 2023-04-21 2024-10-24 Flagship Pioneering Innovations Vii, Llc Rnai agents targeting fatty acid synthase and related methods
WO2024223728A1 (en) 2023-04-27 2024-10-31 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2024223724A1 (en) 2023-04-27 2024-10-31 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2024233308A2 (en) 2023-05-05 2024-11-14 Orna Therapeutics, Inc. Circular rna compositions and methods
AR132624A1 (es) 2023-05-08 2025-07-16 Merck Sharp & Dohme Llc Polinucleótidos que codifican antígenos vp1 de norovirus y usos de los mismos
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
DE102023001946A1 (de) 2023-05-12 2024-11-14 Friedrich-Schiller-Universität Jena, Körperschaft des öffentlichen Rechts Nanopartikel für den Transport von Wirkstoffen mit anionischen Gruppen, Verfahren zu deren Herstellung und deren Verwendung
WO2024236361A1 (en) 2023-05-15 2024-11-21 Takeda Pharmaceutical Company Limited Compositions and methods for delivery of nucleic acids to cells
WO2024236504A1 (en) 2023-05-15 2024-11-21 Takeda Pharmaceutical Company Limited Sequences and methods for delivery of dna and rna
CN116270543B (zh) * 2023-05-19 2023-09-26 清华大学 脂质纳米颗粒在制备通过雾吸或鼻滴给药递送核酸的药物中的用途
WO2024243438A2 (en) 2023-05-23 2024-11-28 Omega Therapeutics, Inc. Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
TW202513091A (zh) 2023-06-09 2025-04-01 美商默沙東有限責任公司 用於人類乳突病毒疫苗之奈米乳液佐劑組合物
WO2024258829A1 (en) 2023-06-12 2024-12-19 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
WO2025006799A1 (en) 2023-06-27 2025-01-02 Capstan Therapeutics, Inc. Extracorporeal and ex vivo engineering of select cell populations from peripheral blood
WO2025006684A1 (en) 2023-06-28 2025-01-02 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides encoding antifusogenic polypeptides
WO2025008774A1 (en) 2023-07-05 2025-01-09 Takeda Pharmaceutical Company Limited Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
WO2025011529A2 (en) 2023-07-07 2025-01-16 Shanghai Circode Biomed Co., Ltd. Circular rna vaccines for seasonal flu and methods of uses
WO2025012756A1 (en) 2023-07-07 2025-01-16 Pfizer Inc. Amphiphilic tlr7/8 adjuvants and uses thereof
WO2025024486A2 (en) 2023-07-25 2025-01-30 Flagship Pioneering Innovations Vii, Llc Cas endonucleases and related methods
US20250243274A1 (en) * 2023-07-31 2025-07-31 Jibe Therapeutics, Inc. Compositions for Redirecting Immunoglobulins to Immune Cells
WO2025029840A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for multiplexed activation and repression of t cell gene expression
WO2025029835A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for modulating il-2 gene expression
WO2025027116A1 (en) 2023-08-01 2025-02-06 Institut Curie Nanoparticles comprising nucleic acid sequences encoding cyclic gmp-amp synthase
WO2025038494A1 (en) 2023-08-11 2025-02-20 Tune Therapeutics, Inc. Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
WO2025042786A1 (en) 2023-08-18 2025-02-27 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides and uses thereof
WO2025049690A1 (en) 2023-08-29 2025-03-06 Orna Therapeutics, Inc. Circular polyethylene glycol lipids
WO2025045142A1 (en) 2023-08-29 2025-03-06 Shanghai Circode Biomed Co., Ltd. Circular rna encoding vegf polypeptides, formulations, and methods of uses
WO2025054236A2 (en) 2023-09-06 2025-03-13 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
WO2025052180A2 (en) 2023-09-07 2025-03-13 Axelyf ehf. Lipids and lipid nanoparticles
WO2025059073A1 (en) 2023-09-11 2025-03-20 Tune Therapeutics, Inc. Epigenetic editing methods and systems for differentiating stem cells
WO2025064475A2 (en) 2023-09-18 2025-03-27 Flagship Pioneering Innovations Vii, Llc Ionizable lipidoid compositions and therapeutic uses thereof
WO2025063214A1 (ja) * 2023-09-22 2025-03-27 国立大学法人東北大学 核酸を内封したリガンド修飾脂質ナノ粒子の製造方法
WO2025072331A1 (en) 2023-09-26 2025-04-03 Flagship Pioneering Innovations Vii, Llc Cas nucleases and related methods
WO2025096807A2 (en) 2023-10-31 2025-05-08 Flagship Pioneering Innovations Vii, Llc Novel therapeutic dna forms
WO2025101501A1 (en) 2023-11-07 2025-05-15 Orna Therapeutics, Inc. Circular rna compositions
TW202535835A (zh) 2023-11-14 2025-09-16 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 可電離類脂質組成物及其治療用途
TW202523695A (zh) 2023-11-22 2025-06-16 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 用於治療非酒精性脂肪性肝病之方法及組成物
WO2025117877A2 (en) 2023-12-01 2025-06-05 Flagship Pioneering Innovations Vii, Llc Cas nucleases and related methods
WO2025129128A1 (en) 2023-12-15 2025-06-19 Vivasor, Inc. Compositions and methods for non-viral delivery of therapeutic compounds
WO2025133115A1 (en) 2023-12-21 2025-06-26 Ose Immunotherapeutics Lipid-based nanoparticles comprising il-35
WO2025132839A1 (en) 2023-12-21 2025-06-26 Glaxosmithkline Biologicals Sa Influenza virus vaccines
US20250375499A1 (en) 2024-01-26 2025-12-11 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
WO2025174825A2 (en) 2024-02-12 2025-08-21 Aera Therapeutics, Inc. Delivery compositions
WO2025180874A1 (en) * 2024-02-27 2025-09-04 Basf Se Substituted 1,3-dioxolane sulfates and their use
WO2025190300A1 (zh) * 2024-03-13 2025-09-18 仁景(苏州)生物科技有限公司 脂质纳米颗粒及脂质纳米颗粒组合物
WO2025194019A1 (en) 2024-03-14 2025-09-18 Flagship Pioneering Innovations Vii, Llc Methods for treating liver fibrosis and non-alcoholic fatty liver disease
WO2025196065A1 (en) 2024-03-20 2025-09-25 Sanofi Novel homocysteine based lipids and their use for delivery of nucleic acids
GB202404607D0 (en) 2024-03-29 2024-05-15 Glaxosmithkline Biologicals Sa RNA formulation
WO2025217275A2 (en) 2024-04-10 2025-10-16 Flagship Pioneering Innovations Vii, Llc Immune cell targeted compositions and related methods
CN118388360B (zh) 2024-04-17 2025-04-04 北京悦康科创医药科技股份有限公司 含有苯环结构的长效脾靶向阳离子脂质化合物、包含其的组合物及用途
US20250353881A1 (en) 2024-05-16 2025-11-20 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
WO2025245188A2 (en) 2024-05-21 2025-11-27 Flagship Pioneering Innovations Vii, Llc Methods of treating liver steatosis and non-alcoholic fatty liver disease
WO2025245111A1 (en) 2024-05-22 2025-11-27 Flagship Pioneering Innovations Vii, Llc Immunoreceptor targeting proteins and related methods
WO2025250751A1 (en) 2024-05-31 2025-12-04 Orna Therapeutics, Inc. Circular rna compositions and methods

Family Cites Families (230)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US3993754A (en) 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
US4086257A (en) 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
CH624011A5 (OSRAM) 1977-08-05 1981-07-15 Battelle Memorial Institute
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
ATE8584T1 (de) 1980-01-16 1984-08-15 Hans Georg Prof. Dr. Weder Verfahren und dialysiereinrichtung zur herstellung von bilayer-vesikeln und verwendung der bilayer-vesikel.
US4598051A (en) 1980-03-12 1986-07-01 The Regents Of The University Of California Liposome conjugates and diagnostic methods therewith
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4476301A (en) 1982-04-29 1984-10-09 Centre National De La Recherche Scientifique Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4588578A (en) 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US4515736A (en) 1983-05-12 1985-05-07 The Regents Of The University Of California Method for encapsulating materials into liposomes
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
FR2567892B1 (fr) 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5545412A (en) 1985-01-07 1996-08-13 Syntex (U.S.A.) Inc. N-[1, (1-1)-dialkyloxy]-and N-[1, (1-1)-dialkenyloxy]-alk-1-yl-n,n,n-tetrasubstituted ammonium lipids and uses therefor
FR2575751B1 (fr) 1985-01-08 1987-04-03 Pasteur Institut Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5405938A (en) 1989-12-20 1995-04-11 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US5453566A (en) 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
JPH02500360A (ja) * 1986-07-28 1990-02-08 リポソーム　テクノロジー，インコーポレイテッド 粘膜組織上での高い保持力を有するリポソーム
US4839175A (en) * 1986-07-28 1989-06-13 Liposome Technology, Inc. Liposomes with enhanced retention on mucosal tissue
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5320906A (en) 1986-12-15 1994-06-14 Vestar, Inc. Delivery vehicles with amphiphile-associated active ingredient
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
DE3851889T2 (de) 1987-06-24 1995-04-13 Florey Howard Inst Nukleosid-derivate.
US4924624A (en) 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5188897A (en) 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
WO1989009221A1 (en) 1988-03-25 1989-10-05 University Of Virginia Alumni Patents Foundation Oligonucleotide n-alkylphosphoramidates
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
CA1340323C (en) 1988-09-20 1999-01-19 Arnold E. Hampel Rna catalyst for cleaving specific rna sequences
GB8822492D0 (en) 1988-09-24 1988-10-26 Considine J Apparatus for removing tumours from hollow organs of body
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
WO1991003162A1 (en) 1989-08-31 1991-03-21 City Of Hope Chimeric dna-rna catalytic sequences
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5286634A (en) 1989-09-28 1994-02-15 Stadler Joan K Synergistic method for host cell transformation
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
DE69033495T2 (de) 1989-10-24 2000-07-20 Isis Pharmaceuticals, Inc. 2'-modifizierte nukleotide
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
GB9009980D0 (en) 1990-05-03 1990-06-27 Amersham Int Plc Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
EP0455905B1 (en) 1990-05-11 1998-06-17 Microprobe Corporation Dipsticks for nucleic acid hybridization assays and methods for covalently immobilizing oligonucleotides
US6465188B1 (en) 1990-06-11 2002-10-15 Gilead Sciences, Inc. Nucleic acid ligand complexes
US6365730B1 (en) 1990-06-19 2002-04-02 Gene Shears Pty. Limited DNA-Armed ribozymes and minizymes
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
CA2088258C (en) 1990-07-27 2004-09-14 Phillip Dan Cook Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
KR100211552B1 (ko) 1990-08-03 1999-08-02 디. 꼬쉬 유전자 발현 억제용 화합물 및 방법
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
US5177196A (en) 1990-08-16 1993-01-05 Microprobe Corporation Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
US5214134A (en) 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5561225A (en) 1990-09-19 1996-10-01 Southern Research Institute Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
JPH06505704A (ja) 1990-09-20 1994-06-30 ギリアド　サイエンシズ，インコーポレイテッド 改変ヌクレオシド間結合
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
DE69123979T2 (de) 1990-10-12 1997-04-30 Max Planck Gesellschaft Abgeänderte ribozyme
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
DE4216134A1 (de) 1991-06-20 1992-12-24 Europ Lab Molekularbiolog Synthetische katalytische oligonukleotidstrukturen
DE4120916A1 (de) * 1991-06-25 1993-01-07 Basf Ag Omega-3 mehrfach ungesaettigte fettsaeurederivate, ihre herstellung und verwendung
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
DE59208572D1 (de) 1991-10-17 1997-07-10 Ciba Geigy Ag Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
WO1993012240A1 (en) 1991-12-17 1993-06-24 The Regents Of The University Of California Gene therapy for cystic fibrosis transmembrane conductance regulator activity (cftr)
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
FR2687679B1 (fr) 1992-02-05 1994-10-28 Centre Nat Rech Scient Oligothionucleotides.
AU3596593A (en) 1992-02-19 1993-09-13 Baylor College Of Medicine Oligonucleotide modulation of cell growth
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
AU687736B2 (en) 1992-05-11 1998-03-05 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting viral replication
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
AU4528493A (en) 1992-06-04 1994-01-04 Regents Of The University Of California, The In vivo gene therapy with intron-free sequence of interest
EP0577558A2 (de) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
EP0786522A2 (en) 1992-07-17 1997-07-30 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecules for treatment of stenotic conditions
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
GB9304618D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Chemical compounds
CA2159631A1 (en) 1993-03-30 1994-10-13 Sanofi Acyclic nucleoside analogs and oligonucleotide sequences containing them
WO1994022891A1 (en) 1993-03-31 1994-10-13 Sterling Winthrop Inc. Oligonucleotides with amide linkages replacing phosphodiester linkages
DE4311944A1 (de) 1993-04-10 1994-10-13 Degussa Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen
WO1995002698A1 (en) 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
US5532130A (en) 1993-07-20 1996-07-02 Dyad Pharmaceutical Corporation Methods and compositions for sequence-specific hybridization of RNA by 2'-5' oligonucleotides
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US6075012A (en) 1994-02-11 2000-06-13 Life Technologies, Inc. Reagents for intracellular delivery of macromolecules
US6989434B1 (en) 1994-02-11 2006-01-24 Invitrogen Corporation Reagents for intracellular delivery of macromolecules
US5591317A (en) 1994-02-16 1997-01-07 Pitts, Jr.; M. Michael Electrostatic device for water treatment
US5631359A (en) 1994-10-11 1997-05-20 Ribozyme Pharmaceuticals, Inc. Hairpin ribozymes
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US5534499A (en) 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
WO1995035301A1 (en) 1994-06-22 1995-12-28 Megabios Corporation Cationic amphiphiles
FR2722506B1 (fr) 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
AU3559695A (en) 1994-09-30 1996-04-26 Inex Pharmaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
DE69527206T2 (de) 1994-09-30 2003-02-27 Inex Pharmaceuticals Corp., Vancouver Mittel zum einbringen polyanionischer materialien in zellen
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
AU3889595A (en) 1994-10-05 1996-05-02 Amgen, Inc. Method for inhibiting smooth muscle cell proliferation and oligonucleotides for use therein
US5627159A (en) 1994-10-27 1997-05-06 Life Technologies, Inc. Enhancement of lipid cationic transfections in the presence of serum
US5783683A (en) 1995-01-10 1998-07-21 Genta Inc. Antisense oligonucleotides which reduce expression of the FGFRI gene
JP3583505B2 (ja) * 1995-05-10 2004-11-04 花王株式会社 新規な第４級アンモニウム塩及びそれを含有する柔軟剤組成物
US5747470A (en) 1995-06-07 1998-05-05 Gen-Probe Incorporated Method for inhibiting cellular proliferation using antisense oligonucleotides to gp130 mRNA
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
AU705549B2 (en) 1995-06-07 1999-05-27 Promega Biosciences, Inc. Phosphonic acid-based cationic lipids
US20030069173A1 (en) 1998-03-16 2003-04-10 Life Technologies, Inc. Peptide-enhanced transfections
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
DE69634084T2 (de) 1995-06-07 2005-12-08 Inex Pharmaceuticals Corp. Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
WO1996040961A1 (en) 1995-06-07 1996-12-19 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
EP0830368A1 (en) 1995-06-07 1998-03-25 Genta Incorporated Novel carbamate-based cationic lipids
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5811406A (en) 1995-06-07 1998-09-22 Regents Of The University Of California Dry powder formulations of polynucleotide complexes
AU707947B2 (en) 1995-07-21 1999-07-22 Promega Biosciences, Inc. Novel amide-based cationic lipids
US6339173B1 (en) 1996-07-22 2002-01-15 Promega Biosciences, Inc. Amide-based cationic lipids
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
US5877220A (en) 1997-03-06 1999-03-02 Genta, Incorporated Amide-based oligomeric cationic lipids
US6034135A (en) 1997-03-06 2000-03-07 Promega Biosciences, Inc. Dimeric cationic lipids
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6743171B1 (en) 1997-04-02 2004-06-01 Henry M. Bowles Relocatable mental function testing gateway
US6235310B1 (en) * 1997-04-04 2001-05-22 Valentis, Inc. Methods of delivery using cationic lipids and helper lipids
DE69841002D1 (de) 1997-05-14 2009-09-03 Univ British Columbia Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln
US6835395B1 (en) 1997-05-14 2004-12-28 The University Of British Columbia Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
US6110745A (en) 1997-07-24 2000-08-29 Inex Pharmaceuticals Corp. Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
EP1129064B1 (en) 1998-11-12 2008-01-09 Invitrogen Corporation Transfection reagents
US6656498B1 (en) * 1998-11-25 2003-12-02 Vanderbilt University Cationic liposomes for gene transfer
US6649780B1 (en) 1998-12-22 2003-11-18 Valentis, Inc. Cationic lipids
RU2148349C1 (ru) * 1999-01-05 2000-05-10 Всероссийский научно-исследовательский институт консервной и овощесушильной промышленности Способ производства комбикормового премикса
US6852334B1 (en) 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
US7094423B1 (en) 1999-07-15 2006-08-22 Inex Pharmaceuticals Corp. Methods for preparation of lipid-encapsulated therapeutic agents
AU771706B2 (en) 1999-07-15 2004-04-01 University Of British Columbia, The Methods and apparatus for preparation of lipid vesicles
MXPA02002107A (es) 1999-08-27 2003-08-20 Inex Pharmaceuticals Corp Composiciones para estimular la secrecion de citoquina e inducir una respuesta inmune.
EP1261620A2 (en) * 2000-02-07 2002-12-04 Roche Diagnostics Corporation Cationic amphiphiles for use in nucleic acid transfection
US20070026394A1 (en) 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
US7189705B2 (en) 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
US6543484B1 (en) 2000-08-15 2003-04-08 Roderick Highsmith Waste water disposal system
AU2002214854A1 (en) 2000-10-25 2002-05-06 Inex Pharmaceuticals Corporation Lipid formulations for target delivery
CA2427068A1 (en) 2000-10-27 2002-05-02 Invitrogen Corporation Method for introducing antisense oligonucleotides into eucaryotic cells
RU2322500C2 (ru) 2000-12-01 2008-04-20 Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. Малые молекулы рнк, опосредующие интерференцию рнк
WO2002069369A2 (en) 2000-12-08 2002-09-06 Coley Pharmaceutical Gmbh Cpg-like nucleic acids and methods of use thereof
WO2002087541A1 (en) 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Lipid-based formulations for gene transfer
US20040142892A1 (en) 2001-04-30 2004-07-22 The University Of British Columbia Autogene nucleic acids encoding a secretable RNA polymerase
US20040063654A1 (en) 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
US7223887B2 (en) 2001-12-18 2007-05-29 The University Of British Columbia Multivalent cationic lipids and methods of using same in the production of lipid particles
AU2003237864B2 (en) 2002-05-15 2008-12-18 California Pacific Medical Center Delivery of nucleic acid-like compounds
US7901708B2 (en) 2002-06-28 2011-03-08 Protiva Biotherapeutics, Inc. Liposomal apparatus and manufacturing methods
MXPA05007651A (es) 2003-01-16 2005-10-26 Univ Pennsylvania Composiciones y metodos para la inhibicion por arnsi de la molecula de adhesion intercelular-1.
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
AU2004246904B2 (en) 2003-06-18 2010-02-04 Biolab Ltd. Sphingolipids polyalkylamine conjugates for use in transfection
SG190613A1 (en) 2003-07-16 2013-06-28 Protiva Biotherapeutics Inc Lipid encapsulated interfering rna
EP1664316B1 (en) 2003-09-15 2012-08-29 Protiva Biotherapeutics Inc. Polyethyleneglycol-modified lipid compounds and uses thereof
JP4764426B2 (ja) * 2004-06-07 2011-09-07 プロチバ バイオセラピューティクス インコーポレイティッド カチオン性脂質および使用方法
AU2005252273B2 (en) 2004-06-07 2011-04-28 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
WO2006002538A1 (en) 2004-07-02 2006-01-12 Protiva Biotherapeutics, Inc. Immunostimulatory sirna molecules and uses therefor
US20060051405A1 (en) 2004-07-19 2006-03-09 Protiva Biotherapeutics, Inc. Compositions for the delivery of therapeutic agents and uses thereof
AU2005289588B2 (en) 2004-09-24 2011-12-22 Alnylam Pharmaceuticals, Inc. RNAi modulation of ApoB and uses thereof
WO2006053430A1 (en) 2004-11-17 2006-05-26 Protiva Biotherapeutics, Inc. Sirna silencing of apolipoprotein b
WO2006074546A1 (en) 2005-01-13 2006-07-20 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
US20060228406A1 (en) 2005-03-17 2006-10-12 Invitrogen Corporation Transfection reagent for non-adherent suspension cells
WO2006138380A2 (en) * 2005-06-15 2006-12-28 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
JP5639338B2 (ja) 2005-07-27 2014-12-10 プロチバ バイオセラピューティクス インコーポレイティッド リポソームの製造システムおよび製造方法
US8101741B2 (en) 2005-11-02 2012-01-24 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
CA2927045A1 (en) 2006-10-03 2008-04-10 Muthiah Manoharan Lipid containing formulations
CA3252166A1 (en) 2008-01-02 2025-11-29 Arbutus Biopharma Corp Screening method for selected amino lipid-containing compositions
US20110117125A1 (en) 2008-01-02 2011-05-19 Tekmira Pharmaceuticals Corporation Compositions and methods for the delivery of nucleic acids
US20110065774A1 (en) 2008-01-31 2011-03-17 Alnylam Pharmaceuticals Chemically modified oligonucleotides and uses thereof
CA2721380A1 (en) * 2008-04-15 2009-10-22 Protiva Biotherapeutics, Inc. Silencing of csn5 gene expression using interfering rna
US8058069B2 (en) 2008-04-15 2011-11-15 Protiva Biotherapeutics, Inc. Lipid formulations for nucleic acid delivery
WO2009132131A1 (en) * 2008-04-22 2009-10-29 Alnylam Pharmaceuticals, Inc. Amino lipid based improved lipid formulation
WO2010036962A1 (en) * 2008-09-25 2010-04-01 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
WO2010042877A1 (en) * 2008-10-09 2010-04-15 Tekmira Pharmaceuticals Corporation Improved amino lipids and methods for the delivery of nucleic acids
CN105152939A (zh) 2008-11-10 2015-12-16 阿尔尼拉姆医药品有限公司 用于递送治疗剂的脂质和组合物
CA3045126A1 (en) 2009-05-05 2010-11-11 Arbutus Biopharma Corporation Methods of delivering oligonucleotides to immune cells
US20110071208A1 (en) 2009-06-05 2011-03-24 Protiva Biotherapeutics, Inc. Lipid encapsulated dicer-substrate interfering rna
EP2449114B9 (en) 2009-07-01 2017-04-19 Protiva Biotherapeutics Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
EP2449106B1 (en) 2009-07-01 2015-04-08 Protiva Biotherapeutics Inc. Compositions and methods for silencing apolipoprotein b
EP2506879A4 (en) 2009-12-01 2014-03-19 Protiva Biotherapeutics Inc PREPARATIONS OF SNALP CONTAINING ANTIOXIDANTS
US20130123338A1 (en) 2010-05-12 2013-05-16 Protiva Biotherapeutics, Inc. Novel cationic lipids and methods of use thereof
US10077232B2 (en) 2010-05-12 2018-09-18 Arbutus Biopharma Corporation Cyclic cationic lipids and methods of use
US8865675B2 (en) 2010-05-12 2014-10-21 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein B
WO2012000104A1 (en) 2010-06-30 2012-01-05 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
BR122022001262B1 (pt) 2010-11-15 2022-09-27 Life Technologies Corporation Compostos de transfecção contendo amina e complexo de transfecção

Similar Documents

Publication Publication Date Title
JP2012505250A5 (OSRAM)
JP2011509258A5 (OSRAM)
JP7753190B2 (ja) 核酸の送達のための改善された脂質ナノ粒子
EP3010514B1 (en) Double-stranded antisense nucleic acid with exon-skipping effect
KR20220084366A (ko) CAR mRNA 전달을 위한 지질 나노입자 및 그것의 제형
US20220396556A1 (en) Lipid and Lipid Nanoparticle Formulation for Drug Delivery
US10183977B2 (en) Stabilized STAT3 decoy oligonucleotides and uses therefor
JP2018520685A (ja) Ｂ型肝炎ウイルスに対する組成物および薬剤ならびにその使用
JP2014518612A5 (OSRAM)
JP2015500835A5 (OSRAM)
JP2019522972A (ja) 遺伝性障害の治療のための改善された特徴を有する二環式スキャフォールド部分を含むプレｍＲＮＡスプライススイッチング又は調節オリゴヌクレオチド
JP2012531469A5 (OSRAM)
TW201828995A (zh) 用於肌肉萎縮症之外顯子跳躍寡聚物結合物
JP2018518201A (ja) ｓｉＲＮＡ、ｓｉＲＮＡを含む医薬組成物及び結合体、並びにそれらの応用
EP3076950A1 (en) Means for lung specific delivery
US20220288231A1 (en) Methods and compositions for reducing gene or nucleic acid therapy-related immune responses
US12410213B2 (en) Polypeptides self-assembling into nanoparticles
AU2017205650A1 (en) Therapeutic compositions and methods for treating hepatitis b
EP4626400A1 (en) Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
JP6506270B2 (ja) アンチセンスオリゴヌクレオチド組成物
WO2024067885A1 (en) Antisense oligonucleotide, compositions and pharmaceutical formulations thereof for exon skipping
JP2025520111A (ja) Ｒｎａアジュバント、その方法及び使用
WO2025090663A1 (en) Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
Fang USING QΒ VLPS TO PACKAGE, PROTECT, AND DELIVER IN VIVO PRODUCED RNAS